Feedback
Settings

Settings

Goto Application

1,970 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 197
1.102024129442POLYMER-GEKOPPELTE ANTIKÖRPER UND ANTIKÖRPERFRAGMENTE
DE - 16.04.2026
Int.Class A61K 47/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
58obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyacrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
 Appl.No 102024129442 Applicant Universität Potsdam, Körperschaft des öffentlichen Rechts Inventor Glebe Ulrich

Die Erfindung betrifft ein Konjugat umfassend mindestens ein Polymer und mindestens einen Antikörper oder mindestens ein Antikörperfragment, wobei das Polymer ausgewählt ist aus Poly(dimethyl acrylamid) (PDMA), Poly(oligoethylen glykol methacrylat) (POEGMA), Poly(2-hydroxypropyl methacrylamid) (PHPMA), Poly(vinylpyrrolidon) (PVP), Poly(2-methylsulfinyl)ethyl acrylat (PMSEA), Poly(6-O-methacyloyl-D-galactopyranose) (PMAGP), Acrylsäure (PAA), Poly(carboxybetain acrylat) (PCBA), Poly(vinylphosphonsäure) (PVPA), Poly(vinylbenzoesäure) (PVBzA), Poly(propylacrylsäure) (PPAA), Poly(styrolsulfonsäure) (PSS), Polyglycerol (PG) und Polyäpfelsäure (PMA) und das mindestens eine Antikörperfragment vorzugsweise mindestens einen Einzeldomänenantikörper (Nanobody) umfasst. Die Erfindung betrifft ferner die medizinische Verwendung des Konjugats, sein Herstellungsverfahren und Kits für dessen Anwendung. embedded image

2.WO/2026/075998EXTRACELLULAR VESICLES AND THERAPEUTIC APPLICATIONS THEREOF
WO - 09.04.2026
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/US2025/048758 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor XU, Xiaowei
The present invention provides compositions comprising extracellular vesicles (EVs) comprising a targeting protein, such as an anti-DR5 targeting protein, to target DR5+ cells. Also provided are nucleic acids and expression vectors encoding the targeting protein, methods for producing the surface-modified EVs, and methods for treating diseases or disorders, such as cancer with the surface-modified EVs, including EVs loaded with one or more therapeutic agents.
3.2026509262抗ＴＤＰ－４３結合分子およびその使用
JP - 17.03.2026
Int.Class C12N 15/13
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
 Appl.No 2025551955 Applicant エイシー　イミューン　ソシエテ　アノニム Inventor アフロズ，タリク
本発明は、分子量４３ｋＤａのトランス活性応答ＤＮＡ結合性タンパク質（ＴＡＲＤＢまたはＴＤＰ－４３とも）の分野にある。本発明は、ＴＤＰ－４３特異的結合分子、特に抗ＴＤＰ－４３抗体またはその抗原結合性断片もしくは誘導体、およびその使用に関する。本発明は、前頭側頭型認知症（ＦＴＤ）、筋萎縮性側索硬化症（ＡＬＳ）、アルツハイマー病（ＡＤ）、パーキンソン病（ＰＤ）、慢性外傷性脳症（ＣＴＥ）、および辺縁系優位型加齢性ＴＤＰ－４３脳症（ＬＡＴＥ）を含むがそれらに限らない、ＴＤＰ－４３凝集体に関連する疾患、障害、および／または異常を診断、防止、改善、および／または処置するための手段および方法を提供する。
4.WO/2026/046228DENDRITIC POLYMER CONJUGATE AND PREPARATION METHOD THEREFOR
WO - 05.03.2026
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/CN2025/117207 Applicant SUZHOU RENOLYNX THERAPEUTICS CO., LTD. Inventor ZHU, Lingjian
The present disclosure relates to a dendritic polymer conjugate and a preparation method therefor. Specifically, the present disclosure relates to a dendritic polymer conjugate or a pharmaceutically acceptable salt thereof, and use thereof in medicine. The conjugate comprises a dendritic polymer loaded with a drug and a pharmacokinetic modifier, and an antibody conjugated to the dendritic polymer.
5.202025107612Diagnostisches Reagenz für die Analytik von sCD14-ST
DE - 26.02.2026
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No 202025107612 Applicant DiaSys Diagnostic Systems GmbH Inventor

Diagnostisches Reagenz zur qualitativen und quantitativen Bestimmung des sCD14-ST-Antigens, wobei das diagnostische Reagenz eine Reagenzkomponente aufweist, die eine wässrige Suspension von Polymerpartikeln mit kovalent daran gebundenen Antikörpern gegen sCD14-ST ist, wobei an den Polymerpartikeln wenigstens 2 unterschiedliche monoklonale Antikörper gegen sCD14-ST kovalent gebunden sind.

6.121517576能够结合VEGF的Fc融合蛋白及其用途
CN - 13.02.2026
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 202511133805.8 Applicant 长春金赛药业有限责任公司 Inventor 徐立忠
本发明提供了能够抑制VEGF信号传导的多肽构建体，含有所述多肽构建体的药物组合物，以及相关用途。
7.121313822PD-L1单抗递送系统、其制备方法及应用
CN - 13.01.2026
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No 202311704890.X Applicant 西安交通大学医学院第二附属医院 Inventor 惠文涛
本发明公开了PD‑L1单抗递送系统、其制备方法及应用，属于药物技术领域。本发明通过NHS酯化将BPA‑PEG9与PD‑L1单抗的氨基偶联，形成BPA6‑aPDL1；通过酰胺键将邻苯二羟基的葡萄糖衍生物麦芽仿生酸MA接枝到类脂质两亲性分子PEG1.5k‑DSPE，形成MA4‑PEG1.5k‑DSPE，即MA4‑PD；然后，BPA6‑aPDL1通过硼酸酯键与MA4‑PD反应最终形成递送体系MB‑aPDL1。该递送体系不仅能够成功将PD‑L1跨血脑屏障递送到肿瘤部位，还可精准释放PD‑L1单抗，使其只在肿瘤区域富集，延长抗体的滞留时间，增加其锚定肿瘤的能力，显著降低了免疫相关不良事件的发生。
8.121293307一种肿瘤来源IgG抗体偶联的载CpG人重组铁蛋白纳米肿瘤疫苗
CN - 09.01.2026
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 202511229983.0 Applicant 中国科学院过程工程研究所 Inventor 王连艳
本发明涉及一种肿瘤来源IgG抗体偶联的人重组铁蛋白装载CpG的纳米肿瘤疫苗。本发明的纳米肿瘤疫苗包括人重组铁蛋白核壳结构，表面偶联肿瘤来源IgG抗体，并在其核心携载CpG。本发明还涉及该纳米肿瘤疫苗在治疗黑色素瘤中的应用。
9.WO/2026/011073ANTIBODY DRUG CONJUGATES
WO - 08.01.2026
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/US2025/036294 Applicant YALE UNIVERSITY Inventor GLAZER, Peter
The present disclosure provides an antibody-drug conjugate (ADC) having an antibody, antigen-binding fragment thereof, or cell-penetrating fragment thereof; a linker; and a payload moiety. Compositions including the ADC and methods of using the ADC are also provided.
10.202025001670Vorrichtung zur Blockierung neurotropischer Viren in Nervenbahnen
DE - 27.11.2025
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 202025001670 Applicant Özköylü Murathan Inventor

Vorrichtung zur präventiven Blockierung neurotropischer Viren im peripheren Nervensystem, umfassend ein biochemisches Injektionssystem zur lokalisierten Freisetzung eines neurospezifischen Bindemoleküls, eine Detektionseinheit zur Identifikation von viralen Partikeln in neuromuskulärem Gewebe und eine Rezeptorköderstruktur zur Bindung viraler Glykoproteine mit Affinität zu neuronalen Rezeptoren, dadurch gekennzeichnet, dass die Vorrichtung eine retrograde axonale Virusweiterleitung unterbindet, ohne die Leitfähigkeit des Nervengewebes dauerhaft zu beeinträchtigen.

# -